Now trading at a price of $47.52, Apellis Pharmaceuticals has moved -5.1% so far today on a volume of 678,204, compared to its average of 1,310,730. In contrast, the S&P 500 index moved -0.9%. Apellis Pharmaceuticals shares moved 9.8% over the last 52 weeks, with a high of $70 and a low of $33.32. During this time, the stock underperformed the S&P 500 index by 27.7%. As of January 2022, the company's 50-day average price is $51.0. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The mid-cap Healthcare company has 476 full time employees and is based in Waltham, MA. Apellis Pharmaceuticals has not offered any dividends in the last year.
Overview of the Company's Irregular and Negative Cash Flows with a Downwards Trend:
| 2019-12-31 | 2020-12-31 | 2021-12-31 | |
|---|---|---|---|
| Revenue (k) | $0 | $250,646 | $66,563 |
| Revenue Growth | n/a | n/a | -73.44% |
| Operating Margins | n/a | -85.3% | -805.7% |
| Operating Margins Growth | n/a | n/a | -844.55% |
| Net Margins | n/a | -137.59% | -1121.27% |
| Net Margins Growth | n/a | n/a | -714.94% |
| Earnings Per Share | -$4.9 | -$4.59 | -$8.84 |
| EPS Growth | n/a | 6.33% | -92.59% |
| Free Cash Flow (k) | -$212,829 | -$165,910 | -$564,229 |
| FCF Growth | n/a | 22.05% | -240.08% |
| Capital Expenditures (k) | -$1,693 | -$5,422 | -$1,103 |
| Net Debt / EBITDA | 0.73 | 0.97 | 0.84 |
Apellis Pharmaceuticals Is Overvalued:
Compared to the Healthcare sector's average of 13.21, Apellis Pharmaceuticals has a trailing twelve month price to earnings (P/E) ratio of -6.0 and, based on its EPS guidance of -5.31, an expected P/E ratio of -9.0. The firm's price to earnings growth (PEG) is -0.24, because its current P/E ratio is negative — so in this case the PEG ratio is not a meaningful indicator of the company's valuation. Apellis Pharmaceuticals's price to book (P/B) ratio is 17.1 compared to its sector average of 4.07. The company is likley overvalued in terms of its net tangible assets.
Apellis Pharmaceuticals Benefits From Positive Market Indicators:
16 analysts are following Apellis Pharmaceuticals and have set target prices ranging from $40 to $123 per share. On average, they have given the company a rating of buy. At the current price of $47.52, APLS is trading -37.78% away from its average analyst target price of $76.38 per share, implying an analyst consensus of strong upside potential for the stock.
The company has an above average percentage of its shares sold short since 12.3% of the company's shares are tied to short positions. Institutions own 89.6% of Apellis Pharmaceuticals's shares, while the insider ownership rate stands at 15.1%. The biggest shareholder is Avoro Capital Advisors LLC with a 9% stake in the company worth approximately $481,190,640.
